Aeterna Zentaris

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.

AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble appeared first on InvestorPlace.

If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference

Aeterna Zentaris was one of my previous winners, but a disappointing commercial launch for their flagship product, Macrilen, caused the share price to bleed for most of 2020. The company has been making deals left and right, which brought the share price from around $0.30 to over $3.00 in a few months. I review some of these deals.

Aeterna Zentaris: Revisiting A Past Winner

CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering of 20,509,746 common shares of Aeterna, at a price to the public of $1.45 per share. The gross proceeds from the offering were approximately $29.7 million, before deducting underwriting discounts, commissions and offering expenses payable by Aeterna.

Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 20,509,746 common shares of Aeterna, at a price to the public of $1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,896,552 common shares of Aeterna, at a price to the public of $1.45 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

Alpine 4 Holdings

Ocugen, Inc.

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the run are Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTCMKTS: ALPP), Enzolytics (OTCMKTS: ENZC), and Ocugen (NASDAQ: OCGN).

4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN)

The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) went up 237.37% over the past week. This is why it happened.

AEZS Stock Price Increased 237.37% Over The Past Week: Why It Happened

Aeterna Zentaris (AEZS) stock is soaring higher on Monday with heavy trading even with there being a lack of news about the company. The post AEZS Stock: 7 Things to Know About Aeterna Zentaris as the Biotech Rockets Higher appeared first on InvestorPlace.

AEZS Stock: 7 Things to Know About Aeterna Zentaris as the Biotech Rockets Higher

The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) is trading at over 50% pre-market as of 7:48 AM. This is why it happened.

AEZS Stock Price Increases Over 50% Pre-Market: Why It Happened

- Company secures next step to continue to build-out pipeline of assets

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from Julius-Maximilians-University of Wuerzburg, Germany - Initial step in growth strategy to build-out pipeline of assets - Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –

Aeterna Zentaris to Present at NobleCon17

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive licensing agreement (the “Agreement”) with Consilient Health, Ltd. (“CH” or “Consilient Health”), a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East, for the commercialization in Europe and the United Kingdom of macimorelin, Aeterna's orally available ghrelin agonist, in any diagnostic application, including the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and, subject to receipt of regulatory approval, childhood-onset growth hormone deficiency (“CGHD”).

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021

Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021

Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update

–  Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth

Aeterna Zentaris Provides Corporate Update

- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT -

Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults -

Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology

 – Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency

Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update

CHARLESTON, S.C., Aug.  05, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc . (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today the closing of its previously announced registered direct offering with several institutional investors in the United States for 12,427,876 common shares, at a purchase price of $0.56325 per common share, priced at-the-market under Nasdaq rules. Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 9,320,907 common shares in a concurrent private placement. The warrants have an exercise price of $0.47 per common share, are exercisable immediately and will expire five and one-half years following the date of issuance. The gross proceeds to the Company from the offering totaled approximately $7.0 million, before deducting placement agent fees and offering expenses.

Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market

CHARLESTON, S.C., Aug.  03, 2020  (GLOBE NEWSWIRE) --   Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 12,427,876 common shares at a purchase price of $0.56325 per common share in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $7.0 million.

AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

CHARLESTON, S.C., July  31, 2020  (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the filing of two patent applications on July 22, 2020 related to its substance macimorelin, an orally available ghrelin agonist to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and childhood-onset growth hormone deficiency (“CGHD”).

News for Aeterna Zentaris Stock (AEZS)